Seoul, June 27 (IANS) SK bioscience, a biopharmaceutical arm of South Korea’s SK Group, on Thursday said it has agreed to pay 339 billion won ($243 million) for control of German biotech company IDT Biologika.
According to the company officials, the acquisition of IDT Biologika will give SK bioscience a crucial gateway for its expansion plans in the US and Europe, Yonhap news agency reported.
“The main purpose of this deal is to establish a new growth base and to further expand our core businesses into global markets, including developed countries,” SK bioscience CEO Ahn Jae-yong said.
Under the agreement, SK bioscience will acquire a 60 per cent stake in IDT Biologika from Klocke Group. Klocke Group will also acquire a 1.9 per cent stake in SK bioscience, allowing the two companies to strengthen their partnership.
IDT Biologika, a wholly owned subsidiary of Klocke Group, is one of the top 10 contract development and manufacturing firms in the global vaccine market, according to SK bioscience.
–IANS
rvt/dpb
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
